Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
First Opinion
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Business
STAT+

After the ASCO weekend, cancer drug stocks are moving. Here are your winners and losers

  • Adam Feuerstein

By Adam Feuerstein June 4, 2018

Reprints
Sharon Begley/STAT

Updated at 11:33 am ET with new information and stock prices.

Investors spent the weekend chewing over cancer drug data presented at the American Society of Clinical Oncology annual meeting. It’s Monday, so time to see how the markets are reacting.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

‘Microdosing’ is touted by ’shroomers and Reddit users. Science…
‘Microdosing’ is touted by ’shroomers and Reddit users. Science is starting to test their claims —…
Dope Sick: A harrowing story of best friends, addiction…
Dope Sick: A harrowing story of best friends, addiction — and a stealth killer
Do more moles mean more risk of skin cancer?
Do more moles mean more risk of skin cancer?
Why the world’s smallest wheelchairs are going unused
Why the world’s smallest wheelchairs are going unused
Wary of changes to Medicare Advantage, health insurers put…
Wary of changes to Medicare Advantage, health insurers put up a fight — and exaggerate the…
Strengthen science by funding living evidence synthesis
Strengthen science by funding living evidence synthesis

Recommended Stories